ORIC Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated August 10, 2023, reporting financial results for the fiscal quarter ended June 30, 2023. The filing relates to Item 2.02, Results of Operations and Financial Condition, and incorporates by reference a press release furnished as Exhibit 99.1.
ORIC is a Delaware corporation headquartered in South San Francisco, California. Its common stock trades on the Nasdaq Global Select Market under the symbol ORIC.
Financial Metrics
The filing text provided does not include the financial results press release or clear values for revenue, net income or loss, cash flow, margins, debt, cash, liquidity, or other financial metrics.
Material Changes Versus the Prior Comparable Period
The filing text does not provide sufficient information to assess changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide management guidance, outlook commentary, risk updates, contingencies, or unusual items. Any such information may be contained in the referenced Exhibit 99.1 press release, which is not included in the provided text.
The reported information was furnished under Item 2.02 and Item 9.01 and is expressly not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except where expressly stated.
Key Facts for Investors to Verify
- Obtain and review Exhibit 99.1 for the complete quarterly financial results.
- Verify cash, cash equivalents, marketable securities, operating cash burn, and expected liquidity runway.
- Verify research and development expenses, general and administrative expenses, and net loss for the quarter.
- Review any clinical-development updates, pipeline changes, guidance, financing activity, or material risks included in the press release.
- Confirm whether the company reported any changes in debt, equity issuance plans, or other capital requirements.